Bio Essence Corp (BIOE): Total Liabilities
$2.50M
As of 2025-12-31
$1.66M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.50M | -23.2% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $3.25M | -26.4% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $4.42M | n/c | 2025-03-28, Balance as of period end |
| 2022-12-31 | $4.79M | +15.9% | 2024-04-15, Balance as of period end |
| 2021-12-31 | $4.13M | +13.8% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $3.63M | n/a | 2022-03-31, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Bio Essence Corp (BIOE) | 2025-12-31 | $2.50M | -23.2% |
| Lipocine Inc. (LPCN) | 2025-12-31 | $2.53M | +67.1% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $37.52M | +74.3% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $17.11M | -48.4% |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | $2.52M | -19.0% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $28.89M | +7.5% |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $1.10M | +34.7% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $128.86M | +21.9% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | $37.17M | +21.3% |
Compare BIOE, LPCN, DNTH, RANI side by side · Screen every company in Pharmaceutical Preparations ↗